Searched for
TICAGRELOR
For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...- Will the currency cycle help them? Yes, but very selectively: 10 pharma stocks with upside potential of up to 33%The biggest mistake made in currency cycles is to confuse revenue gain with pure earnings gain. A company may report stronger rupee revenue...
- India strategic launchpad for next wave of obesity careIndia is poised to establish itself as a pivotal hub for semaglutide API manufacturing. Leading pharmaceutical firms are amplifying their p...
- Sound businesses are the best antidote for volatility: 6 large- and mid-cap stocks with an upside potential of up to 30%The market hates uncertainty. Post the big reforms (GST and banking), the markets should have ideally been in upbeat mode this festive seas...
- Alembic gets USFDA nod for generic drugAlembic Pharmaceuticals secured USFDA approval to market generic Ticagrelor tablets, 90 mg, aimed at preventing heart attack and stroke. Th...
- Volatile phases come and go, structural tailwinds are a stronger play: 5 Indian pharma stocks with upside potential of up to 35%There are some sectors which have witnessed something which can be called “second inning”. Which is that in the last two decades, they did ...
- AstraZeneca bets on licencing deals, public-private partnerships for India growthBritish-Swedish drugmaker AstraZeneca is set to launch 15 new products in India from 2023 to 2025, focusing on oncology, cardiovascular, re...
- Medicine for bearish markets: 5 Indian pharma stocks with upside potential of up to 32%There are some sectors which are able to face bears in a better way. The reason, the operating matrix of those sectors is such that rising ...
- Second & better attempt; 5 Indian pharma stocks with upside potential of up to 31%Both, in terms of bottomline and stock price performance, pharma stocks had been under pressure for a long time. Partly this under performa...
- A Healthy Dose! 4 midcap pharma stocks with upside potential of up to 36%After a long period of under performance, pharma stocks have seen interest coming back from institutional investors. This is because some t...
- Finally out of the woods? 4 midcap pharma stocks with an upside potential up to 34 %Pharma stocks had been underperforming for a very long time. Some time USFDA issues, at other instances of pricing pressure in US markets h...
- On a path to recovery: 5 midcap pharma stocks with an upside potential up to 32%As the markets get jittery, select pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are mid-sized In...
- On a path to recovery; 5 mid-cap pharma stocks with an upside potential up to 41%As the markets get jittery, select pharma stocks are back in focus. This tends to happen in bearish markets. Some of them are mid-sized Ind...
- On a path to recovery; 7 mid-cap pharma stocks with an upside potential up to 47 %After the covid tailwinds got over, pharma stocks witnessed a phase of under-performance. However as the markets get jittery, select pharma...
- AstraZeneca working on vaccine to prevent and cure Covid: MD Gagandeep SinghAnglo-Swedish pharma company AstraZeneca has mobilised research efforts to advance the development of a novel coronavirus-neutralising long...
- Torrent Pharmaceuticals puts faith in local market, to focus on new drug launchesThe Ahmedabad-based company, part of the Rs 14,000-crore Torrent Group, is the only domestic pharma co that has invested nearly $1 bn in lo...
- AstraZeneca sues DRL on patentCopies of the drug can be manufactured only after all the patents covering it expire, AstraZeneca’s counsel argued in court on Tuesday.
- AstraZeneca rallies over 37% in June on Forxiga launch; more gains likelyAstraZeneca have broken out of the narrow trading range in June, driven by two positive news flows. The stock has rallied 37.41% since June...
- Sun Pharma, AstraZeneca seal distribution dealThe drug majors have entered into a distribution services agreement to distribute AstraZeneca's heart disease treatment drug 'Axcer' in Ind...
- AstraZeneca launches heart drug 'Brilinta' in IndiaAstraZeneca Pharma India today launched its patented antiplatelet drug Brilinta, used to prevent heart attack, after receiving approval fro...
Load More
